Possible Sale of Ariad Pharmaceuticals

Reuters recently reported that drugmaker Baxalta Inc. is in talks with Ariad Pharmaceuticals Inc. to buy Ariad. Ariad is a developer of leukemia and lung-cancer treatments and their shares have jumped approximately 43% to a two-year high of $10.

Bloomberg reported that Baxalta was working with bankers to buy an unidentified US-based oncology specialist valued at about $2 billion.

Time will tell if the deal goes through, but it is worthwhile to watch these companies in the interim.